BioCentury
ARTICLE | Clinical News

BIM 23A760: Phase II started

March 22, 2010 7:00 AM UTC

Ipsen began an open-label, dose-escalation, international Phase II trial of subcutaneous BIM 23A760 in about 100 patients. ...